Carlyle Spend $3.8B on Baxter Kidney Care Unit

According to the businesses, Baxter has agreed to pay $3.8 billion to private equity company Carlyle Group for its Vantive renal care company. In this investment, Carlyle and Atmas Health are collaborating.

After closing the Vantive purchase, Baxter plans to increase operating revenues by 4% to 5% annually.

Originally, Baxter intended to split out Vantive as a separate, publicly listed business. However it announced that it was in talks to sell the business with anonymous private equity investors.

Baxter CEO José Almeida stated: “Today’s announcement represents another critical step forward in the strategic transformation process we announced in early 2023. As a result of this proposed transaction, Baxter will emerge a more focused and more efficient company.”